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Aspergillus-related lung diseaseAlexey Amchentsev*, Navatha Kurugundla, Anthony G. SalehDepartment of Medicine/Pulmonary & Critical Care, New York Methodist Hospital, 506 Sixth Street,
Brooklyn, NY 11214, USASummaryAspergilli are ubiquitous fungi with branched septate hyphae. Aspergillus produces a wide
variety of diseases determined by the inoculating dosage, the ability of the host to resist infec-
tion at local and systemic levels and the virulence of the organism. These entities differ clin-
ically, radiologically, immunologically, and in their response to various therapeutic agents.
Although the fungus can affect any organ system, the respiratory tract is involved in >90%
of affected patients. A broad knowledge is required to timely diagnose and aggressively treat
the potentially lethal manifestations of Aspergillus-related pulmonary diseases.
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 To review the clinical spectrum of Aspergillus-related
lung disease.
 To discuss the standardized criteria for the diagnosis of
allergic bronchopulmonary aspergillosis.
 To review the factors that predispose to the develop-
ment of invasive pulmonary aspergillosis.
 To review the latest diagnostic methods used in diag-
nosis of Aspergillus-related lung disease.
 To discuss recent advances in diagnostic and thera-
peutic approaches to respiratory diseases caused by
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Aspergillus is a ubiquitous soil-dwelling organism that is
found in humid areas, damp soil or agricultural environ-
ments. It is also found on grain, cereal, moldy flour, and
organic decay or decomposing matter. Since the first
description of aspergillosis in animals by Mayer in 1815
and the first human case of aspergillosis described in 1842
by Bennett,1 more than 350 species that belong to the
genus Aspergillus have been described. Only a few are
known to be pathogenic in humans such as Aspergillus
fumigatus which is responsible for more than 90% of
invasive disease,2 followed by A. niger, A. nidulans,
A. terreus, A. clavatus, A. flavus, A. niveus, and
A. ustus.3 In a recent review of 300 cases with proven
IPA, A. terreus was the second most common species,
isolated with a frequency of 23%.4
Aspergillus can cause a variety of clinical syndromes
ranging from mild, transient asthma to serious, dissemi-
nated disease, particularly in the immunosuppressed host.
206 A. Amchentsev et al.Aspergillus-related pulmonary disorders may be classified
into four clinical categories depending on whether the
host is atopic, non-atopic or immunosuppressed (see
Fig. 1).
This article reviews the clinical spectrum of Aspergillus-
related lung disease, highlighting the risk factors, clinical




Allergic bronchopulmonary aspergillosis is a hypersensi-
tivity reaction to Aspergillus antigens, mostly due to
A. fumigatus. The incidence of ABPA varies from 6% to 20%
of all patients with asthma.5 It occurs with equal frequency
in both sexes. Most patients are under age 35 years at the
time of diagnosis. In patients with cystic fibrosis, the
prevalence of ABPA is 0.5e15%.6
The pathogenesis of ABPA is not completely understood.
There is no relation between the intensity of exposure to
airborne Aspergillus spores and rates of sensitization to the
fungus as measured by skin testing.7 Aspergillus-specific
IgE-mediated type I hypersensitivity reactions, specific
IgG-mediated type III hypersensitivity reactions, and
abnormal T-lymphocyte cellular immune responses all
appear to play important roles in its pathogenesis.8e10 ABPA
is characterized pathologically by mucoid impaction of the
bronchi, eosinophilic pneumonia, and bronchocentric
granulomatosis in addition to the histological features of
asthma.6 ABPA is usually suspected on clinical grounds, but
requires immunological and radiological confirmation in an
appropriate clinical setting. The disease manifests itself
with low-grade fever, cough, wheezing, brownmucus plugs,
and progressive shortness of breath. Pleuritic chest pain and
hemoptysis are frequent. Repeated episodes of bronchial
obstruction, inflammation, and mucoid impaction can lead
to bronchiectasis, fibrosis, and respiratory compromise.6
Chest radiologic findings may show fleeting pulmonary
infiltrates in the upper lobes and central in location during
acute exacerbations. The radiological signs representing
the thickened and inflamed bronchi may be seen on chest













c. Lung abscess and multiple cavities
d. Aspergillosis bronchitis/ 
tracheobronchitis
e. Infarction




Figure 1 Pulmonary aspergbronchiectasis and pulmonary fibrosis at later stages.
Computed tomography (CT) findings in allergic broncho-
pulmonary aspergillosis consist primarily of mucoid
impaction and bronchiectasis involving predominantly the
segmental and subsegmental bronchi of the upper lobes. In
one study, the combination of bronchiectasis with mucous
plugging, atelectasis, peripheral airspace consolidation, or
ground-glass attenuation (with or without mosaic perfusion
or air trapping) enabled radiologists to make a correct
diagnosis of ABPA in 84% of cases.11 In approximately 30% of
patients, the impacted mucus has high attenuation or
demonstrates frank calcification at CT. Differential diag-
nosis includes other causes of mucoid impaction such as
endobronchial lesions, bronchial atresia, and
bronchiectasis.
There is no individual test to establish the diagnosis of
ABPA.6,12 Typically, total serum IgE is elevated, and sputum
cultures reveal Aspergillus spp. Serum IgE could be used as
a marker for flare-ups and responses to therapy.13
Immediate skin test reactivity to A. fumigatus antigens
and elevated levels of serum IgG and IgE antibodies to
Aspergillus are usually documented.14
Greenberger and Patterson have standardized the
criteria for the diagnosis of ABPA (see Fig. 2), not all of
which need to be present for the diagnosis to be made.13,15
A staging system for ABPA has been developed to cate-
gorize the differing presentations of ABPA. These stages are
not necessarily progressive phases and do not necessarily
occur in order.16 Stage I is the acute initial presentation
with asthma, markedly elevated IgE level, peripheral
eosinophilia, upper and middle lobe infiltrates, and IgE and
IgG antibodies to A. fumigatus. In Stage II (remission stage),
the IgE falls but usually remains elevated, eosinophilia is
absent, and no infiltrates are noted on the chest radio-
graph. Serum IgG antibodies to Aspergillus antigen may be
slightly elevated. Stage III is recurrence with the same
findings as in stage I. Stage IV (the corticosteroid-depen-
dent stage) occurs in patients who have asthma in which
control of symptoms is dependent on chronic use of high-
dose corticosteroid therapy and exacerbations are marked
by worsening asthma, radiographic changes, and an
increase in IgE level may occur. Frequently, the chest CT
scan will show central bronchiectasis. In stage V (fibrotic















Diagnostic criteria for ABPA
• Asthma
• Immediate skin reactivity to Aspergillus
• Serum precipitins to A fumigatus 
• Increased serum IgE and IgG to A fumigatus
• Total serum IgE>1000 ng/ml
• Current or previous pulmonary infiltrates
• Central bronchiectasis
• Peripheral eosinophilia (1000 cells/ml)
Figure 2 Diagnostic criteria for ABPA.
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reversible, with no long-term sequelae. The final diagnosis
is usually confirmed by use of clinical, radiographic, and
immunologic criteria.
Treatment of ABPA aims to control episodes of acute
inflammation and to limit progressive lung injury. Gluco-
corticoids are most commonly used, although there is
increasing evidence of benefit from combined therapy with
itraconazole. The 2008 Infectious Diseases Society of
America guidelines on the treatment of aspergillosis
recommend that therapy of ABPA should consist of
a combination of glucocorticoids and itraconazole.17
Treatment with corticosteroids leads to relief of broncho-
spasm, resolution of radiographic infiltrates, and reduction
in serum total IgE and peripheral eosinophilia.18,19 Two
weeks of daily therapy of oral prednisone (0.5 mg/kg/day),
followed by gradual tapering, has been recommended for
new ABPA infiltrates.20,21 Most patients, however, require
prolonged low-dose corticosteroid therapy to control their
symptoms and minimize relapses.
Itraconazole has been effective in improving symptoms,
facilitating weaning from corticosteroids, decreasing
Aspergillus titers, and improving radiographic abnormali-
ties and pulmonary function.22 Itraconazole is thought to
work by reducing the antigenic stimulus for bronchial
inflammation.17 The antifungal effects can be inferred by
the ability of itraconazole to reduce specific Aspergillus
IgG.23 One study showed that 46% of patients treated with
itraconazole (200 mg b.i.d. for 16 weeks), had a significant
response, which was defined as a 50% reduction in the
corticosteroid dose, a decrease of at least 25% in the serum
IgE concentration, and a 25% improvement in exercise
tolerance or pulmonary function test results, or the reso-
lution or absence of pulmonary infiltrates.24 Itraconazole
may augment the activity of corticosteroids via inhibition of
their metabolism, which may lead to abnormal ACTH
stimulation and adrenal insufficiency.25 The usual duration
of therapy is 3e6 months.6 Total serum IgE serves as
a marker of ABPA disease activity, and should be checked
6e8 weeks after the initiation of therapy, then every
8 weeks for 1 year after that to determine a baseline range
for each patient.26
Patients may develop clinicopathologic syndromes
related to ABPA. The mucoid impaction syndrome may be
seen without asthma or other features of the disease. The
patient usually presents with a cough and expectoration of
mucus plugs. The mucus plugging may lead to atelectasis.
In patients presenting with bronchocentric granulomatosis,necrotizing granulomas obstruct and destroy the bronchi-
oles. The Aspergillus hyphae can be identified within the
granulomas in up to 50% of patients with bronchocentric
granulomatosis.27 The eosinophilic infiltrates and fibrosis
are present in the lung parenchyma; however, there is no
tissue or vascular invasion by the Aspergillus. Clinically, the
patients are almost always asthmatic and have a persistent
cough with typical findings of elevated peripheral blood
eosinophil count, elevated total serum IgE, and circulating
IgE antibodies to Aspergillus species. Sputum gram stain
and culture occasionally reveal Aspergillus.28,29
The chest radiograph usually shows solitary or multiple
pulmonary nodules that may be mistaken for malignancies.
Aspergillus rarely has been implicated in the etiology of
eosinophilic pneumonitis.
The typical presentation of these patients is cough,
dyspnea, and fever associated with peripheral pulmonary
infiltrates, and an elevation of Aspergillus IgE levels. The
diagnosis usually is confirmed by biopsy, and patients
respond well to corticosteroid therapy.30,31
When a patient develops hypersensitivity granulomatous
inflammation of the distal airways and lung parenchyma, it
is called extrinsic allergic alveolitis, also known as, hyper-
sensitivity pneumonitis. This is related to intense or
recurring inhalation of various antigens, including thermo-
philic bacteria, fungi, bird excreta, and chemical agents.
The acute form of the disease presents within hours of
exposure to the antigens with dyspnea, cough, fever, and
myalgia. In advanced cases, there may be features of right-
sided heart failure. The chest radiograph usually shows
interstitial and alveolar nodular infiltrates. In the chronic
stage, a reticulo-interstitial pattern and honeycombing may
be seen. Serum levels of IgG antibodies to Aspergillus are
elevated when the disease is due to Aspergillus.32
The management of the acute form of hypersensitivity
pneumonitis includes avoiding further exposure to the
offending agents and corticosteroid therapy.33,34IPA
Invasive pulmonary aspergillosis (IPA) is characterized by
proliferation of fungal mycelia in the pulmonary paren-
chyma. This disease is due to tissue invasion with the fungi.
It is uncommon and occurs primarily in the setting of
immunosuppression. There have been less than 20 cases
reported in healthy patients. Invasion of the pulmonary
vasculature may result in hemorrhagic infarction. Factors
that predispose to the development of invasive aspergillosis
include neutropenia, hematopoietic stem-cell and solid
organ transplantation, prolonged and high-dose cortico-
steroid therapy, hematological malignancy, cytotoxic
therapy, advanced AIDS, and chronic granulomatous
disease. The risk factors are summarized in (see Fig. 3).
Neutropenia is the most important risk factor, and it is
estimated that IPA accounts for 7.5% of all infections in
neutropenic patients following induction therapy for acute
myelogenous leukemia.35 The risk of IPA in these patients is
increased with the duration of neutropenia and is esti-
mated to be 1% per day for the first 3 weeks, after which
time it increases to 4% per day. The epidemiology of IPA is
changing and now less than one-third of all patients
Major risk factors for invasive
pulmonary aspergillosis 
1. Prolonged neutropenia (<500 cells/mm3 for>10 days) 
or neutrophil dysfunction
2. Corticosteroid therapy (especially >3 weeks, high-dose 
therapy)
3. Transplantation (highest risk is with lung and bone
marrow)
4. Hematologic malignancy (risk is higher with leukemia)
5. Cytotoxic therapy
6. AIDS (risk increases with lower CD4 count)
Figure 3 Major risk factors for invasive pulmonary
aspergillosis.
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nosis.36 Another significant risk factor for IPA is solid organ
transplantation, especially after lung and hematopoietic
stem-cell transplant. It is estimated that 5% of BMT recip-
ients develop IPA with mortality rates ranging between 30%
and 80%.36e38 The mortality rate of IPA exceeds 90% in
hematopoietic stem-cell transplantation recipients.39,40 IPA
also has been reported increasingly in patients with HIV
infection. The response to therapy is particularly poor in
the HIV-infected population.41
Rarely, IPA has been reported in the mildly immuno-
compromised, such as patients with alcoholism, chronic
liver disease, or diabetic ketoacidosis. In a recent review of
545 patients with invasive aspergillosis, BMT was the most
frequent risk factor (32%; autologous BMT, 7%; allogeneic
BMT, 25%), followed by hematologic malignancy (29%), solid
organ transplantation (9%), and AIDS (8%). In 2% of patients,
no underlying risk factors were identified.2
The characteristic clinical presentation of invasive
aspergillosis is a neutropenic individual who is receiving
chemotherapy and having persistent fevers despite treat-
ment with multiple antibiotics. The lower respiratory tract
is almost always the primary focus of infection as a result of
the inhalation of Aspergillus spores. Patients present with
symptoms that are usually non-specific, and consistent with
acute bacterial or fungal pneumonia (fever, cough, sputum
production, and dyspnea). Other symptoms that are
significant and raise the possibility of IPA are pleuritic chest
pain (due to vascular invasion leading to small pulmonary
infarcts) and hemoptysis that is typically mild but can be
massive. IPA is one of the most common causes of hemop-
tysis in neutropenic patients; and has been reported to be
associated with cavitation that occurs with neutrophil
recovery.42
With the predilection of Aspergillus to invade blood
vessels, IPA commonly leads to areas of infarction and
hemorrhage in the primary organ (usually the lungs), and
the organism spreads hematogenously to other organs,
most commonly the brain and rarely the skin, kidneys,
pleura, heart, esophagus, or liver.1 In angioinvasive asper-
gillosis with vascular dissemination, thrombosis and
necrosis are common. The symptoms are intense pleuritic
chest pain, sudden dyspnea, tachypnea and hemoptysis.
Aspergillus can cause a bronchitis/tracheobronchitis
with severe inflammation of the airways, characterized by
ulcers and membrane formation; most often in AIDS
patients and lung transplant recipients.1,43 Hyphae invadethe airways and form plugs consisting of mycelia, inflam-
matory cells, and necrotic debris. These plugs along with
the membranes produce airway obstruction resulting in
wheezing and dyspnea. Approximately 10% of patients
who have invasive aspergillosis develop tracheobronchitis
either alone or with pneumonia. Aspergillus sinusitis can
occur in patients with HIV infection.44 Pleural effusions
or empyemas are rare manifestation of invasive
aspergillosis.45,46
The diagnosis of IPA remains challenging, and the clini-
cian must maintain a high index of suspicion for invasive
aspergillosis in patients with risk factors. Definitive diag-
nosis of invasive aspergillosis is best made by demonstrating
the characteristic branching septate hyphae in a lung tissue
sample along with a culture that is positive for Aspergillus
from the same site. Histopathological diagnosis, by exam-
ining lung tissue obtained by thoracoscopic or open-lung
biopsy, remains the‘‘gold standardr‘‘ in the diagnosis of
IPA.47
Histopathological examination also allows for the
exclusion of other diagnoses, such as malignancy or non-
fungal infectious diseases. Other fungi such as Fusarium
and Scedosporium may have comparable appearances,
highlighting the importance of performing a culture for the
precise identification of the fungus.
The significance of isolating Aspergillus spp. in sputum
samples depends on the immune status of the patient. In
one study of elderly hospitalized patients with Aspergillus
isolated from the sputum, 92% were consistent with
colonization, and only 4.5% had IPA.48 In the immuno-
compromised host sputum culture positivity may be the
only indication of IPA. In immunocompetent patients,
isolation of Aspergillus spp. from the sputum almost
always represents colonization with no clinical conse-
quences and antifungal therapy is generally not indicated.
Some studies have shown that sputum samples that are
positive for Aspergillus in patients with leukemia or in
those who have undergone BMT have a positive predictive
value of 80e90%.49e51
Alternatively, negative sputum samples do not rule out
IPA, and it has been shown that negative sputum studies
have been found in 70% of patients with established
IPA.49,52 Blood cultures rarely have positive results.53
The chest X-ray may be normal or reveal nodular
lesions, patchy infiltrates, or cavitary lesions.54,55 In one
large series of patients, only 10% had a normal chest
X-ray.2 The chest CT scan, especially with high-resolution
images, is a much more helpful tool in detecting early
changes that are not present on chest radiographs. The use
of high-resolution chest CT scans in patients with sus-
pected IPA has been associated with better outcomes,
most likely due to earlier diagnosis. Patterson et al showed
that 85% of chest CT scans had findings suggestive of IPA.2
Bronchoscopy and/or high resolution CT were performed in
a study of 33 patients.56 The sensitivity of bronchoalveolar
lavage (BAL) fluid and washings were 33% and 50%
respectively. CT signs of fungal infection were found in 16
(84%) of 19 episodes. The characteristic CT scan findings
are multiple nodules and the halo sign (which is an early
radiologic sign that appears as a zone of low attenuation
due to hemorrhage surrounding the pulmonary nodule)
which is primarily seen in neutropenic patients early in the
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crescent sign, which is a crescent-shaped lucency in the
region of the original nodule secondary to necrosis.57,58 In
spite of the above referenced findings, neither sign is
sensitive. The halo sign may be found as a result of
metastasis, bronchoalveolar carcinoma, bronchiolitis
obliterans organizing pneumonia, eosinophilic pneumonia,
or other fungal infection.59
Fungal smear and culture of BAL fluid is helpful in the
diagnosis of IPA, particularly in patients with diffuse lung
involvement. The BAL fluid has high specificity attaining
97%,60 but has low sensitivity. The transbronchial biopsies
do not improve the overall diagnostic yield and are asso-
ciated with increased risks.61 Bronchoscopy may also be
useful in detecting Aspergillus antigens in the BAL fluid,
and excluding other infections.
Open or thoracoscopic lung biopsies are generally the
best way to diagnose pulmonary problems in immunocom-
promised patients, but even this procedure is associated
with approximately 20% false-negative results.62 When BAL
and bronchoscopic biopsy are negative, and a high clinical
suspicion of invasive aspergillosis persists, an open lung
biopsy should be performed.
The poor candidacy of many patients with suspected
invasive aspergillosis for surgical or other diagnostic
procedures has prompted interest in non-invasive ways for
diagnosis. Galactomannan is a cell wall glycoprotein that is
released by Aspergillus during growth. The Food and Drug
Administration recently approved a double-sandwich ELISA
for the detection of galactomannan in serum for the diag-
nosis of IPA. Serum galactomannan can be detected several
days before the presence of clinical signs, an abnormal
chest radiograph, or positive culture. The galactomannan
enzyme immunoassay (EIA) demonstrates proven reliability
in patients with hematologic malignancy; however, the
reported sensitivity varies from 44% to 90%.63,64 False-
positive results have been reported in patients receiving
b-lactam antibiotics or in those infected with the dimorphic
fungi Histoplasma capsulatum or Blastomyces dermatiti-
dis.65 Polymerase chain reaction (PCR) has also been eval-
uated and appears promising as a potential diagnostic
modality, but PCR is not yet commercially available for the
diagnosis of Aspergillus,66 and is often associated with
false-positive results, because it does not discriminate
between colonization and infection.
Detection of serum (1/3)-b-D-glucan, a fungal cell wall
constituent, has recently received FDA approval, and is
a highly sensitive and specific test for invasive deep mycosis,
including candidiasis, fusariosis, and aspergillosis, that could
be useful in immunocompromised patients.67 Unfortunately,
the presence of (1/3)-b-D-glucan is not specific for Asper-
gillusbut is indicative of invasive fungal infectionwith several
possible fungal pathogens.68 The utility of this assay in non-
neutropenic and in allogeneic HSCT recipients at high risk for
IPA is not yet known. Patients with severe immunosuppres-
sion, particularly after BMT have a poor response to therapy
compared to less severely immunosuppressed patients (28%
vs. 51%, correspondingly).2 Also, the response is better when
IPA was limited to the lung as opposed to patients with
disseminated infection (40% vs. 18%, respectively).2
When a high suspicion of IPA exists empiric therapy
should be started, especially in immunocompromisedpatients. Most deaths due to IPA occur during the first
6 weeks after the start of therapy.17,69
Three classes of antifungal agents are available for the
treatment of aspergillosis: polyenes, azoles, and echino-
candins. Historically, amphotericin B has been the major
antifungal drug used in patients with invasive aspergillosis;
however, voriconazole is now generally considered the drug
of choice for the treatment of invasive aspergillosis and was
recommended for this indication by the 2008 Infectious
Diseases Society of America guidelines on the treatment of
aspergillosis.17,70,71
A study which compared voriconazole to amphotericin B
as the primary therapy for IPA showed that voriconazole
had almost 20% higher response rate and a higher survival at
week 12.72 These findings suggest that voriconazole is
superior to standard amphotericin B in patients with inva-
sive aspergillosis. Voriconazole has a milder side-effect
profile, and is much better tolerated than amphotericin B,
but has a significant number of drug-to-drug interactions.73
If the diagnosis of invasive aspergillosis has not been made,
and the patient is at high risk of zygomycosis, voriconazole
is not recommended because it does not have activity
against the zygomycetes.
Itraconazole is considered a second-line agent for the
treatment of aspergillosis and is rarely used in immuno-
suppressed patients with invasive disease. Voriconazole has
greater intrinsic activity against Aspergillus species, and
both the intravenous and the oral forms are better toler-
ated than itraconazole. The variable bioavailability and
potential toxicities of itraconazole limit its use in patients
with invasive disease, and the IV formulation has only
limited data to support its use. In a large nonrandomized
study itraconazole resulted in complete or partial response
in 39% and in a failure to respond to treatment in 26% of
patients with IPA. The results were particularly poor in
allogeneic BMT recipients and AIDS patients.74 For allergic
syndromes and in less invasive disease, itraconazole
remains a useful alternative.
One of the newest triazoles, posaconazole, is similar in
structure to itraconazole. It is well tolerated, but steady-
state levels are not obtained for up to 1 week, potentially
decreasing its efficacy as primary therapy. Nevertheless, it
is effective and safe as salvage therapy in patients with
invasive aspergillosis refractory to standard antifungal
therapy.75,76 Long-term use of posaconazole in the treat-
ment of refractory invasive fungal infections appears to be
safe; the most common side effects in one study were
gastrointestinal in nature.77
The most widely used treatment for invasive aspergil-
losis is amphotericin-B. The treatment is recommended to
continue until the infection appears to be clinically
resolved and the immunosuppression improving. The
response rate varies greatly from 20% to 83%.78 Lipid based
preparations of amphotericin B have been used in an effort
to minimize side effects. These preparations enable the
infusion of higher doses of amphotericin B with less toxicity
and are indicated in patients who are at high risk for
nephrotoxicity, or have toxic reactions while receiving
amphotericin B.79
The echinocandins (caspofungin, micafungin, and ani-
dulafungin) are a novel class of antifungal agents with
a unique mechanism of action. They are effective agents
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if the patient cannot tolerate first-line agents.70,80
Although all three of the currently available echinocandins
have demonstrated activity against Aspergillus, caspo-
fungin is the only one currently approved by the FDA as
second-line treatment for invasive aspergillosis. There are
no prospective randomized studies that show improved
efficacy with combination therapy (rather than single
agents) in the management of primary IPA. Combination
therapy of an echinocandin with either a lipid formulation
of amphotericin B or triazole agent appears promising, but
cannot be recommended for the routine treatment of
primary IPA. Controlled randomized prospective studies
are needed to document the value of this approach.
Surgery can be used to debride necrotic tissue and to
remove infected tissue in patients with invasive aspergil-
losis; however, many neutropenic patients also have
profound thrombocytopenia, which may complicate or
preclude surgery as a therapeutic option. Surgery should be
considered in cases of massive hemoptysis, pulmonary
lesions close to the great blood vessels, or immunocom-
promised patients undergoing resection of residual local-
ized pulmonary lesions.81,82
There is a possible benefit from adding immunomodu-
latory agents (colony-stimulating factors) or interferon-
gamma to the treatment of neutropenic patients suspected
to have IPA. This may decrease the degree of immunosup-
pression, in addition to the use of antifungals for the
treatment of IPA. Colony-stimulating factors stimulate the
bone marrow to produce more neutrophils, and have been
shown to augment the phagocytic activity of neutrophils
against fungi, including Aspergillus spp.83,84Chronic necrotizing pulmonary aspergillosis
Chronic necrotizing pulmonary aspergillosis (CNPA) is the
description applied to cavitary lung disease, chronic respi-
ratory symptoms, and serum precipitating antibodies to
Aspergillus spp. Several reports describe direct invasion of
Aspergillus into the lung parenchyma, with CNPA thus
described as a subacute or non-angioinvasive form.85
Several of these cases, however, report progressive
damage to the lung parenchyma without clear evidence of
tissue invasion. The term chronic cavitary pulmonary
aspergillosis (CCPA) has been applied to the formation and
expansion of multiple pulmonary cavities.86 It was found
that these patients usually are middle-aged with evidence
of generalized immunosuppression in the form of diabetes
mellitus, malnutrition, corticosteroid or radiation therapy,
collagen vascular diseases or underlying lung diseases.87,88
These patients usually present with fever, cough,
sputum production, and weight loss for several months, but
some patients may be asymptomatic.87 Radiologic findings
in CNPA progress slowly over months or years and include
unilateral or bilateral segmental areas of consolidation with
or without cavitation or adjacent pleural thickening, and
multiple nodular areas of increased opacity.89,90
A fungal ball may be seen in nearly one half of the cases.87
Other helpful but non-diagnostic tests include serum IgG
antibodies to Aspergillus (positive results in >90% of the
patients) and immediate skin reactivity to Aspergillusantigens.91 Confirmation of the diagnosis requires a histo-
logical demonstration of tissue invasion by the fungus, and
the growth of Aspergillus species on culture. The yield of
transbronchial biopsy specimens or percutaneous aspirates
is relatively poor, and a thoracoscopic or open-lung biopsy is
rarely performed in these patients. Confirmation of the
diagnosis is thus difficult, and delayed diagnosis is common,
which may contribute to the morbidity and mortality asso-
ciated with CNPA. The combination of characteristic clinical
and radiological findings and either serological results posi-
tive for Aspergillus or the isolation of Aspergillus from
respiratory samples is highly indicative of CNPA.86
Patients with CNPA respond to systemic antifungal
therapy, but this may be a life-long requirement. Ampho-
tericin B was initially used, with favorable results.87,92
Itraconazole has been used as a maintenance drug, and its
slight inhibition of the immune response is deemed to be
useful for recovery from chronic pulmonary aspergillosis.92,93
Recently, voriconazole has emerged as a primary
therapy for CNPA, with a complete or partial response seen
in 43% of patients, and improvement or stability in 80%.94
Treatment is best evaluated by using multiple variables
such as change of weight, energy levels, improvement of
symptoms, decreasing levels of inflammatory markers and
total serum IgE level, improvement in infiltrates, and
a reduction in cavity size.91
Surgery should be reserved for patients with reasonable
respiratory reserve and no other treatment options. It may
be appropriate for patients with severe hemoptysis if
embolization fails. Mortality varies in reports from 10 to
39% when using itraconazole.92Aspergilloma
When Aspergillus colonizes a pre-existing lung cavity,
a fungus ball composed of fungal hyphae, inflammatory
cells, fibrin, mucus, and tissue debris, may form an asper-
gilloma (mycetoma). It is generally thought that the pres-
ence of Aspergillus in pulmonary cavities reflects
saprophytic colonization and not actual tissue invasion.
Aspergilloma is the most common and best recognized form
of pulmonary involvement due to Aspergillus.
Many cavitary lung diseases are complicated by aspergil-
lomas, including tuberculosis and sarcoidosis (most common),
followed by bronchiectasis, bronchial cysts, bullae, anky-
losing spondylitis, neoplasms, and pulmonary infection.95e97
Sometimes these patients are asymptomatic; however,
up to 75% of patients present with hemoptysis98 or
productive cough, chest pain, dyspnea, fever, weight loss,
or clubbing. Life threatening bleeding may occur from
bronchial blood vessels, and may be due to local invasion of
blood vessels lining the cavity, endotoxins released from
the fungus, or mechanical irritation of the exposed vascu-
lature inside the cavity.99e101 Although aspergillomas are
usually single, they may also be present bilaterally.
The diagnosis of pulmonary aspergilloma is usually based
on the clinical and radiographic features, combined with
serological or microbiologic evidence of Aspergillus spp.
At radiography, mycetomas are characterized by the
presence of solid, round or oval masses with a soft-tissue
opacity within a lung cavity.102 Typically, the mass is
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size and shape, resulting in the ‘‘crescent’’ or Monod’s
sign.103,104 The aspergilloma usually moves when the patient
changes position. Differential diagnosis for the air crescent
sign include angioinvasive aspergillosis, echinococcal cyst,
tuberculosis, Rasmussen aneurysm in a tuberculous cavity,
lung abscess, bronchogenic carcinoma, hematoma, and
P. jiroveci pneumonia.90,102,105 Aspergillomas are often
associated with thickening of the cavity wall and adjacent
pleura.106,107 In such cases, pleural thickening may be the
earliest radiographic sign before any visible changes are seen
within the cavity. Reversibility of the pleural thickening cor-
responding to the resolution of intracavitary fungal material
has been demonstrated at follow-up radiography and it
suggests that the thickening of the cavity wall and pleura is
due to a hypersensitivity reaction.106
While chest radiography does not clearly delineate
a cavity, CT scanning of the lungs can be used to demon-
strate a cavity and any intracavitary structures. Magnetic
resonance imaging findings are particularly informative and
can be used in cases where better resolution of the
pathology is required.108 The natural history of aspergil-
loma is variable. In the majority of cases, the lesion
remains stable, however, in approximately 10% of cases, it
may decrease in size or resolve spontaneously without
treatment.102 Sputum cultures for Aspergillus spp. are
positive only in 50% of cases.109
Serum IgG antibodies to Aspergillus are positive in
almost every case, but may be negative in patients on
corticosteroid therapy.110 Aspergillus antigen has been
recovered from the BAL of patients with aspergilloma, but
the diagnostic value of this test is variable.22,111
There is no consensus on the treatment of aspergilloma.
Treatment is considered only when patients become
symptomatic, usually with hemoptysis. Many treatment
strategies such as inhaled, intracavitary, and endobronchial
instillations of antifungal agents have been tried and
reported in small numbers of patients, without consistent
success.112e114 In patients with massive hemoptysis from
aspergilloma, administration of amphotericin B percuta-
neously guided by CT scan can be effective, with resolution
of hemoptysis within a few days.115 The role of intrave-
nously administered amphotericin B is uncertain, and some
small studies failed to show a benefit.116
Itraconazole has been used with some reduction in the
size of the fungus ball, especially in Europe and Japan, and
has been shown to penetrate into the aspergilloma.117
Itraconazole is a useful agent for aspergilloma manage-
ment, and mainly because of its high tissue penetration an
oral form has been used, with radiographic and symp-
tomatic improvement in one half to two-thirds of patients,
and occasional patients having a complete response.118e120
The major limitation of itraconazole is that it works slowly
and would not be useful in cases of life-threatening
hemoptysis.22
Surgical resection of the cavity and removal of the fungus
ball is usually indicated in patients with recurrent hemop-
tysis. Surgical treatment is associated with relatively high
mortality rates up to 23%.121,122 It is important to risk stratify
these patients to determine if they would tolerate surgery.
Bronchial artery embolization should be considered as
a temporary measure in life threatening hemoptysis or inpatients who are not surgical candidates; but hemoptysis
usually recurs due to the presence of massive collateral
blood vessels.123 The role of newer antifungal azoles such
as voriconazole in the treatment of aspergilloma has yet to
be determined.
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Answer the following questions:
1. Which of the following statements is true regarding
Aspergillus, please select the following statements:
a. Aspergillus fumigatus is responsible for less than
80% of invasive disease.
b. Aspergillus terreus is known to be pathogenic only in
animals.
c. Aspergillus is a ubiquitous organism found in cereal,
grain, decomposing matter
d. Only 100 species were identified belonging to genus
Aspergillus so far
e. Aspergillus can cause a variety of clinical syndromes
I. a, b, c, d True
II. All False
III. c, e True
IV. All True
V. c, d True
2. Which of the following statement regarding allergic
bronchopulmonary aspergillosis are correct:
a. It occurs with equal frequency in both sexes.
b. Allergic bronchopulmonary aspergillosis is a hyper-
sensitivity reaction to Aspergillus antigens.
c. In patients with cystic fibrosis, the prevalence of
ABPA is up to 15%.
d. There is no relation between the intensity of expo-
sure to airborne Aspergillus spores and rates of
sensitization to the fungus as measured by skin
testing.
212 A. Amchentsev et al.e. The symptoms are low-grade fever, cough, wheezing,
brown mucus plugs, and progressive shortness of
breath.
I. a, c, d True
II. All False
III. b, d True
IV. All True
V. a, e True
3. Select all applicable statements describing features of
Aspergilloma:
a. Mycetoma is created through invasion and destruc-
tion of lung parenchyma.
b. Hemoptysis is most common presenting sign.
c. Air crescent sign on radiography.
d. Magnetic resonance imaging can be used in cases
where better resolution of the pathology is
required.
e. Treatment should be started when patients are
asymptomatic.
f. Surgical treatment is associated with mortality of
60%.
I. a, b, c, d True
II. b, c, d True
III. c, d True
IV. All True
V. All False
4. Choose the correct statements regarding chronic
necrotizing pulmonary aspergillosis:
a. Confirmation of the diagnosis requires a histological
demonstration of tissue invasion by the fungus, and
the growth of Aspergillus species on culture.
b. Diabetes mellitus, malnutrition, corticosteroid and
radiation therapy are not implemented as risk
factors for development of chronic necrotizing
pulmonary aspergillosis.
c. Surgery should be the first treatment option for
patients diagnosed with chronic necrotizing pulmo-
nary aspergillosis.
d. Radiologic findings in CNPA include only unilateral
areas of consolidation and without cavitation.
e. Patients with CNPA do not respond to systemic
antifungal therapy.
I. a True
II. a, b True
III. b, d True
IV. c, d True
V. All False
5. Identify the correct statements regarding invasive
pulmonary aspergillosis:
a. The lower respiratory tract is almost always the
primary focus of infection as a result of the inhala-
tion of Aspergillus spores.
b. Very rarely IPA has been reported in healthy patients.
c. Neutropenia, hematopoietic stem-cell and solid
organ transplantation, hematological malignancy,cytotoxic therapy, advanced AIDS are the factors
that predispose to the development of invasive
aspergillosis.
d. The mortality rate of IPA exceeds 90% in hemato-
poietic stem-cell transplantation recipients.
e. Voriconazole is now generally considered the drug of
choice for the treatment of invasive aspergillosis
I. a True
II. a, b True
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